Long acting GLP-1 receptor agonist (injectable)
Albiglutide 50 mg injection every 2 weeks
ALBI_SC_50MG_Q2W
Related
- All doses pooled: Albiglutide injection
- Albiglutide 100 mg injection every 4 weeks
- Albiglutide 4 mg injection once weekly
- Albiglutide 15 mg injection once weekly
- Albiglutide 30 mg subcutaneous once weekly
- Albiglutide 15 mg injection every 2 weeks
- Albiglutide 30 mg injection every 2 weeks
- Albiglutide 50 mg injection every 4 weeks
- Albiglutide flexible dose injection once weekly
- Albiglutide 50 mg subcutaneous once weekly
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.85 (0.59 to 5.27) | 0.26 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.86 (2.38 to 9.80) | 0.26 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 6.21 (2.34 to 16.46) | 0.25 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.34 (0.45 to 3.45) | 0.57 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.51 (0.35 to 12.43) | 0.37 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.94 (0.05 to 15.33) | 0.45 |